Viatris Inc. (VTRS)
NASDAQ: VTRS · IEX Real-Time Price · USD
11.78
+0.18 (1.55%)
At close: May 3, 2024, 4:00 PM
11.87
+0.09 (0.76%)
After-hours: May 3, 2024, 7:03 PM EDT
Viatris Employees
Viatris had 38,000 employees on December 31, 2023. The number of employees increased by 1,000 or 2.70% compared to the previous year.
Employees
38,000
Change (1Y)
1,000
Growth (1Y)
2.70%
Revenue / Employee
$405,971
Profits / Employee
$1,439
Market Cap
14.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 38,000 | 1,000 | 2.70% |
Dec 31, 2022 | 37,000 | 0 | - |
Dec 31, 2021 | 37,000 | -8,000 | -17.78% |
Dec 31, 2020 | 45,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Quest Diagnostics | 48,000 |
Teva Pharmaceutical | 37,851 |
Dr. Reddy's Laboratories | 25,863 |
Revvity | 11,500 |
BioMarin Pharmaceutical | 3,401 |
Neurocrine Biosciences | 1,400 |
Sarepta Therapeutics | 1,314 |
VTRS News
- 3 days ago - Viatris to Participate in the BofA Securities 2024 Health Care Conference - PRNewsWire
- 4 days ago - Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health - PRNewsWire
- 19 days ago - Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 - PRNewsWire
- 20 days ago - Viatris Appoints Corinne Le Goff as Chief Commercial Officer - PRNewsWire
- 4 weeks ago - UK watchdog says Theramex-Viatris deal raises competition concerns - Reuters
- 4 weeks ago - Teva, Viatris win new chance to challenge J&J schizophrenia drug patent - Reuters
- 4 weeks ago - Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States - PRNewsWire
- 5 weeks ago - Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline - PRNewsWire